GLP1R and ileus: Populations commonly treated with GLP-1 receptor agonists or SGLT2 inhibitors—such as individuals with long-standing diabetes, obesity, prior abdominal surgery, or malignancy—frequently have baseline risk factors for ileus or mechanical obstruction [3,4].